A Peptide Data Pond in One Page
Peptide Test Wholesale Peptids A peptide data pond is three layers over one immutable raw copy: the original instrument capture, a structured record layer for batches and their analytical children, and a derived layer for peak tables, features and model outputs. The raw copy never changes; everything else can be rebuilt from it.
The case for that structure is measurable. 一个 2022 assessment of public chromatographic metadata found that 70% of chromatographic setup descriptions in public repositories were incomplete, and only 20.8% (312 的 1,501) were complete and correct enough to reuse (Harrieder et al., Metabolomics, 2022). The same study’s repository-by-repository split shows MetaboLights at 174 的 468 descriptions complete (37.2%) and Metabolomics Workbench at 276 的 1,033 (26.7%). Those are public repositories whose submitters value data sharing, and the authors note the figures may overestimate correctness elsewhere.
The regulatory reason to keep raw capture intact is separate from the reuse argument. MHRA defines raw data as the first capture of information, whether on paper or electronically, and metadata as data that describe attributes and give context and meaning, forming an integral part of the original record (MHRA GxP Data Integrity Guidance, 修订 1, 行进 2018). MHRA’s position that dynamic raw data must stay dynamic follows from the same definition: a printed chromatogram is a static record and cannot serve as the raw data.
要点: A peptide data pond is raw capture, structured records and derived features in three layers, with the raw copy immutable and every derived artifact rebuildable from it.
Structured identifiers can improve querying and provenance. A shared drive can also contain controlled, traceable records; regulations require preservation and meaning, not a particular database schema or foreign-key implementation.
The Minimum Record Set for a Synthesis Batch and Its Analytical Children
That separation of layers only pays off if the records themselves are specified, so the minimum architecture separates a batch record from its analytical children, and each child carries its own identifiers, method reference and result fields. A single flat table with one row per lot cannot hold the joins described in the next section, and it forces unrelated measurements into shared columns.
The industry’s common QC field pattern is a useful starting point, 不是规格. Custom-synthesis suppliers typically document analytical HPLC for purity, 质谱鉴定, peptide content or net peptide weight, and a certificate of analysis issued with an HPLC chromatogram and an MS spectrum; optional add-ons include endotoxin testing, counter-ion analysis, water content by Karl Fischer and optical rotation. Treat that as the field set the schema must accommodate, and check any supplier’s actual field list against its own documents.
|
场地 |
层 |
Required or useful |
笔记 |
|---|---|---|---|
|
Batch identifier |
批 |
Required |
Persistent, never reused across projects |
|
顺序和修改 |
批 |
Required |
Structured, not free text (see the modification section) |
|
Synthesis method and resin |
批 |
Required |
Versioned reference to a method record |
|
Scale and yield |
批 |
Required |
Units explicit |
|
反离子形式 |
批 |
Required |
TFA and acetate are different materials |
|
Certificate of analysis |
批 |
Required |
Attachment plus structured result fields |
|
Aliquot identifier |
Analytical child |
Required |
Parent batch foreign key |
|
Injection and run identifier |
Analytical child |
Required |
Parent aliquot foreign key |
|
方法版本 |
Analytical child |
Requ Synthetic Peptide Factory ired |
Links to change-controlled method table |
|
HPLC purity result |
Analytical child |
Required |
Value, unit, 积分参数 |
|
MS identity result |
Analytical child |
Required |
Observed versus theoretical mass |
|
Peptide content |
Analytical child |
Required |
Method named (氮, 紫外线, gravimetric) |
|
卡尔费休水分含量 |
Analytical child |
Useful |
Required if content is corrected for water |
|
Endotoxin result |
分析型 Usa Peptides child |
Useful |
Method and limit stated |
|
Optical rotation |
Analytical child |
Useful |
Solvent and temperature stated |
警告: Material described in this blueprint is research-use-only in the peptide-supply context. Nothing here supports dosing, 治疗性的, diagnostic or personal-use claims, and a data model should not imply otherwise.
How to Join Synthesis Records to Chromatograms and Mass Spectra Without Filename Glue
Once those records exist, the pond answers the join from synthesis batch to chromatogram and mass spectrum through stored identifiers, not by parsing a filename. The chain runs batch, aliquot, 注射, run, file, processed result, and each link is a foreign key with a timestamp and an operator.
That chain has a formal shape. Provenance modelled as entities and activities (PROV-O) describes a result as generated by an activity, derived from an input entity and attributed to an agent, which is exactly the structure of a reprocessed peak table derived from a raw file (W3C PROV-O Recommendation, 2013). You do not need the ontology to build the join, but you do need its discipline: every derived artifact points at what it came from.
Container formats already reserve space for that discipline. Allotrope’s data format reserves an audit store and checksums alongside the data, in a six-component structure built on HDF5 and intended for long-term archiving of analytical data (Allotrope Data Format v1.5.3 RF, released 30 十一月 2020). For spectra, mzML 1.1.x is the current open specification line, and its own documentation states that peak-list formats lack information about precursor signals and associated acquisition metadata (HUPO-PSI mzML repository).
Workflow order is a recordable object, not a convention. The sequencing control in §11.10(f) 的 21 CFR部分 11 requires operational system checks that enforce permitted sequencing of steps and events, which is what makes synthesis, aliquot, run and review an auditable order rather than a habit (21 病死率 11.10). Batch traceability for peptides depends on that order surviving reprocessing.
警告: A reprocessed peak table written back over the original destroys the join and the audit trail at once. Derived results belong in a new record that points at the raw file, never in place of it.
How Peptide Modifications Should Be Stored So a Model Can Use Them
The join chain carries the batch, but the batch’s own chemistry has to be structured too: a modification is a record with a site, a chemistry, a mass delta and a controlled-vocabulary accession, not a string appended to a sample name. Free-text modification names break both the join and any model that has to reason across batches.
The vocabulary problem is large enough to require an accession system. Unimod documented 1,559 modification entries as of January 2025, a count cited in a 2025 paper on combinatorial modification identification (Lai et al., 2025). A schema that stores modification names as text cannot map reliably onto a vocabulary of that size, and the same paper notes that conventional search methods pre-specify only a limited number of modifications, typically nine.
Search engines treat modifications as search parameters, which is the opposite of a stored fact. Mascot distinguishes fixed, variable and exclusive modifications, tests all possible arrangements of variable modifications and warns that variable modifications should be used sparingly (Matrix Science Mascot help, 未注明日期). If the modification only exists in a search configuration, it is not in the record and a model cannot learn from it.
The chemistry range the schema has to hold is broad. Custom peptide work spans N-terminal modifications such as acetylation, 生物素化, fluorescent labels and PEGylation; side-chain modifications including phosphorylation on serine, threonine and tyrosine, methylation, sulfation and glycosylation; C-terminal modifications such as amidation and ester forms; and special structures including head-to-tail and side-chain cyclization, 二硫化物, stapled and branched peptides, D-amino acids and isotope labelling. Multiple simultaneous modifications are routine, so the record must be one-to-many from the start.
FAIR’s interoperability clause I3 asks that metadata include qualified references to other metadata, which is the principle an accession plus a structured foreign key satisfies (GO FAIR principles, Wilkinson et al., 2016). A modification table built that way is AI-ready without further work; a text field is not.
|
场地 |
例子: phosphoserine |
例子: N-terminal acetyl |
|---|---|---|
|
地点 |
成为, residue position 12 |
N-末端 |
|
Chemistry class |
磷酸化 |
乙酰化 |
|
质量增量 |
+79.966 和 |
+42.011 和 |
|
Vocabulary accession |
Unimod accession |
Unimod accession |
|
证据 |
MS/MS site localization Gh Peptides |
MS/MS terminal fragment |
|
Method reference 多肽工厂供应商 |
Search configuration version |
Search configuration version |
纯度, 身份, 内容, Stability and Assay Suitability Are Five Different Fields
Structured modifications are one half of the vocabulary discipline; the other half is keeping the quality attributes apart, because purity, 身份, 内容, stability and assay suitability are five separate result fields that answer five different questions and are validated by different tests. Collapsing them into one “quality” column is the most common schema error in peptide records.
我Q2(R2) describes performance characteristics for analytical procedures according to their intended use. It does not mandate this article’s five-field data schema or assign the same validation characteristics to every method.
The guideline also renamed its own vocabulary. Its glossary deliberately replaces “validation characteristic” with “performance characteristic,” described as a technology-independent description of a characteristic that ensures the quality of the measured result (我Q2(R2) glossary). A schema that still labels columns with the superseded Q2(R1) list will not match current method-validation reports.
Stability and assay suitability sit outside that table and need their own fields. Stability is a time-and-condition result with a study identifier; assay suitability is a method-level judgement recorded against a specific procedure. Neither is derivable from a purity percentage, and a purity percentage alone does not establish compound identity, which is why purity, 身份, 方法, lot number and documentation have to be reviewed together.
The practical consequence is a field per attribute, each with its own method reference, unit and acceptance criterion. A model trained on a merged “quality score” learns the merge, 不是化学.
What Must Be Traceable Before an AI Layer Sits on Top
Determine whether Part 11 applies and evaluate all relevant controls, system validation, 程序, training and retention. Access permissions and an audit-table implementation alone do not establish compliance. Scale the system to its risks and intended use.
-
Validation of systems, including the ability to discern invalid or altered records.
-
Accurate and complete copies in human-readable and electronic form.
-
Protection of records for accurate and ready retrieval through the retention period.
-
Access limited to authorized individuals.
-
Secure, 计算机生成的, time-stamped audit trails that do not obscure previous information.
-
Operational checks enforcing permitted sequencing of steps and events.
-
Authority checks on who can sign, alter or perform an operation.
-
Device checks on the validity of the data source.
-
Documented education, training and experience for system users.
-
Written policies holding individuals accountable for actions under their electronic signatures.
-
Controls over systems documentation, including revision and change control with an audit trail.
The change-control clause covers method versions. §11.10(k) requires revision and change control procedures maintaining an audit trail of time-sequenced development and modification of systems documentation, which is what a method-version table has to satisfy (21 病死率 11.10(k)). MHRA’s ALCOA attributes, 可归因的, 清晰易读, 同时期的, 原创且准确, 加完整, 持续的, 持久且可用, describe the same requirement in data-quality terms (MHRA GxP Data Integrity Guidance, 2018). The US regulation supplies the control list; the UK guidance supplies the attributes.
FAIR adds one clause the controls do not state directly: R1.2 asks that data be associated with detailed provenance, which is the research-data version of the audit trail (GO FAIR principles, 2016). Neither FAIR nor the format specifications are endorsed by a regulator, so treat them as design aids, not compliance evidence.
警告: A blueprint that meets these controls is not a validated system. Validation is a documented activity against intended use, and adopting a format or an ontology does not substitute for it.
Where the AI Layer Actually Fits, and Where It Does Not
AI can analyze raw signals, processed features or structured results when the approach is validated for its intended purpose. Preserve source data and processing lineage, control access, and evaluate model credibility according to the decision and applicable framework.
The regulatory framing for AI in a GxP context is still draft. FDA issued draft guidance on AI to support regulatory decision-making for drug and biological products on 7 一月 2025, docket FDA-2024-D-4689, with comments closed 7 四月 2025 (联邦公报, 90 FR 1157, 2025). It proposes a risk-based credibility assessment framework built on a defined context of use, with credibility evidence tailored to that context and dependent on model risk. It is a draft, and the notice states it does not endorse any specific AI approach.
The framework’s shape is instructive even in draft. It runs as a seven-step credibility assessment: define the question of interest, define the context of use, assess model risk, plan credibility activities, execute the plan, document results and deviations, and determine adequacy for the context of use (Goodwin analysis of the FDA draft, 一月 2025). The step that matters for a data pond is the second: without a defined context of use, no amount of data volume makes a model credible.
The draft’s scope is narrower than laboratory data processing. It covers AI used to produce information supporting regulatory decisions on safety, effectiveness or quality, and it explicitly excludes drug discovery and operational-efficiency uses that do not affect patient safety, drug quality or the reliability of study results (联邦公报, 90 FR 1157). A model that flags likely purity outliers for a reviewer’s attention is an operational aid; a model whose output feeds a specification decision is in scope.
A Decision Rule for Releasing an AI-Ready Data Layer
That boundary is what the release rule tests, because a data layer is ready to carry a model when six checks pass in order, and the first failure stops the release. Apply them to your own system before any model reads from it.
- Retain original records and essential metadata in a form that preserves their meaning and required functionality. Electronic dynamic records may need native data; original paper records are not inherently invalid. Document and verify any conversion or true copy.
-
Every analytical child resolves to its batch without filename parsing. The join chain is stored as identifiers, and a query returns the batch from any chromatogram or spectrum.
-
The eleven §11.10 controls are met or have a documented, risk-assessed gap. The audit-trail and change-control clauses are the ones to test first (21 病死率 11.10).
-
Modifications are accessioned records, not text. Each modification carries a site, 化学, mass delta and vocabulary accession, and multiple simultaneous modifications are representable.
-
纯度, 身份, 内容, stability and assay suitability are separate fields with their own method references, matching the attribute-specific test matrix in ICH Q2(R2) (我Q2(R2), 2023).
-
The model’s context of use is written down before the model is built, with the risk assessment and credibility evidence the FDA draft describes (联邦公报, 90 FR 1157, 2025).
A worked example makes the rule concrete. A batch record carries its identifier, sequence with accessioned modifications, counter-ion form and method versions. Two analytical children point at it: an HPLC purity result with its integration parameters and a mass spectrum with observed and theoretical mass. Both children point at their method versions, and the method-version table carries a change history. A derived peak table sits in its own record, points at the raw files and is never written back over them. The model that reads this layer can answer which batch a spectrum belongs to, which method produced a purity value and what changed between two method versions.
If you want to test the rule against real records, talk to a technical expert or request a batch data-package walkthrough and compare the field set against the table above.
The architecture described is a general blueprint drawn from public regulatory and standards documents, not a description of any supplier’s system.*
常见问题解答
What is a peptide data pond?
A peptide data pond is a three-layer store: an immutable raw capture of instrument files, a structured record layer for synthesis batches and their analytical children, and a derived layer for peak tables, features and model outputs. The raw layer never changes, and every derived artifact can be rebuilt from it.
Can we keep vendor raw formats instead of converting to mzML?
Keep the vendor raw files as the raw record and convert to mzML 1.1.x for sharing and long-term access. The mzML documentation states that peak-list formats lose precursor signals and acquisition metadata, so a peak list is not a substitute for the raw file (HUPO-PSI mzML repository). Conversion is an additional derived artifact, not a replacement.
Does adopting Allotrope or FAIR make the system compliant?
不. Allotrope’s format reserves an audit store and checksums, and FAIR’s R1.2 asks for detailed provenance, but neither is endorsed by a regulator as compliance evidence (Allotrope Data Format; GO FAIR principles). Compliance comes from the controls and the validation, not the container.
Is the FDA AI guidance final?
不. It is draft guidance issued 7 一月 2025, with comments closed 7 四月 2025, and it states that it does not endorse any specific AI approach (联邦公报, 90 FR 1157). Treat its context-of-use and credibility-assessment framework as a design reference, not a requirement.
结论
The blueprint reduces to one rule: keep the raw capture immutable, store the joins as identifiers, and separate the five quality attributes into their own fields. Everything else in an AI-ready analytical workflow follows from those three decisions, and the sources behind them are public regulatory and standards text rather than vendor claims.
The evidence for acting now is the completeness gap. A public repository study found only 20.8% of chromatographic descriptions complete enough to reuse, and those submitters were motivated to share (Harrieder et al., Metabolomics, 2022). Internal records built without a schema tend to look the same, and the cost surfaces when a model or an auditor asks for the join.
The next step is the six-check decision rule applied to one real batch: pull its certificate of analysis, its chromatogram and its mass spectrum, and see whether the system can answer which batch the spectrum belongs to and which method version produced the purity value. If it cannot, the gap is in the record set, not in the model.
